Zevra Therapeutics, Inc. Increase (Decrease) in Inventories
Zevra Therapeutics, Inc. (ZVRA) reported Increase (Decrease) in Inventories of $325.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- Zevra Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was $140.00K, a 63.25% decline year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $185.00K, a 9.76% decline year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $525.00K, a 88.87% decline year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $194.00K, a 66.72% decline year-over-year.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for fiscal 2025 was $1.30M, a 85.29% decline from fiscal 2024.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for fiscal 2024 was $8.87M.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for fiscal 2023 was -$206.00K.
- Zevra Therapeutics, Inc. increase (decrease) in inventories for fiscal 2022 was -$147.00K.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $325.00K 10-Q · filed 2026-08-05 | $850.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $185.00K 10-Q · filed 2026-05-06 | $710.00K derived: sum of 2 quarters · filed 2026-05-06 | $904.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $719.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.10M derived: sum of 3 quarters · filed 2026-08-05 | $1.30M 10-K · filed 2026-03-09 |
| 2025-09-30 | $194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $575.00K derived: sum of 2 quarters · filed 2026-08-05 | $780.00K 10-Q · filed 2025-11-05 | $5.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $586.00K 10-Q · filed 2026-08-05 | $5.30M derived: sum of 3 quarters · filed 2026-08-05 | $5.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $205.00K 10-Q · filed 2026-05-06 | $4.92M derived: sum of 2 quarters · filed 2026-05-06 | $5.50M derived: sum of 3 quarters · filed 2026-05-06 | $6.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.30M derived: sum of 2 quarters · filed 2026-03-09 | $6.29M derived: sum of 3 quarters · filed 2026-03-09 | $8.87M 10-K · filed 2026-03-09 |
| 2024-09-30 | $583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.57M derived: sum of 2 quarters · filed 2025-11-05 | $4.16M 10-Q · filed 2025-11-05 | $4.14M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $991.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.58M 10-Q · filed 2025-08-12 | $3.56M derived: sum of 3 quarters · filed 2025-08-12 | $3.50M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.58M 10-Q · filed 2025-05-13 | $2.57M derived: sum of 2 quarters · filed 2025-05-13 | $2.50M derived: sum of 3 quarters · filed 2025-05-13 | $2.43M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$81.00K derived: sum of 2 quarters · filed 2025-03-12 | -$155.00K derived: sum of 3 quarters · filed 2025-03-12 | -$206.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | -$65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$139.00K derived: sum of 2 quarters · filed 2024-11-13 | -$190.00K 10-Q · filed 2024-11-13 | -$57.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$125.00K 10-Q · filed 2024-08-14 | $8.00K derived: sum of 3 quarters · filed 2024-08-14 | -$233.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$51.00K 10-Q · filed 2024-05-09 | $82.00K derived: sum of 2 quarters · filed 2024-05-09 | -$159.00K derived: sum of 3 quarters · filed 2024-05-09 | -$198.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$108.00K derived: sum of 2 quarters · filed 2024-04-01 | -$147.00K derived: sum of 3 quarters · filed 2024-04-01 | -$147.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$241.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$280.00K derived: sum of 2 quarters · filed 2023-11-07 | -$280.00K 10-Q · filed 2023-11-07 | -$280.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$39.00K 10-Q · filed 2023-08-14 | -$39.00K derived: sum of 3 quarters · filed 2023-08-14 | -$39.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |